Qiagen N.V. (NASDAQ:QGEN) encountered a rise of 14.8% or 693,826 shares in the short positions. The number escalated from 4,705,311 on May 31,2016 to 5,399,137 on June 15,2016. The final interest is 2.4% of the floated stock. The days to cover figure of 5 can be arrived using the average daily exchange of 1,157,566 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Qiagen N.V. (NASDAQ:QGEN): The stock opened at $20.96 on Friday but the bulls could not build on the opening and the stock topped out at $21.40 for the day. The stock traded down to $20.92 during the day, due to lack of any buying support eventually closed down at $21.01 with a loss of -6.16% for the day. The stock had closed at $22.39 on the previous day. The total traded volume was 2,100,162 shares.
The company shares have dropped -13.50% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $28.53 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $21.58 and the 200 Day Moving Average price is recorded at $22.73.
Stocks of Qiagen N.V. (NASDAQ:QGEN) rallied by 1.94% during the past week but lost 2.46% on a 4-week basis. In the past week, the company has outperformed the S&P 500 by 3.63% and the outperformance has advanced to 0.49% for the last 4 weeks period.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.